Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq and its blockbuster cancer drug Avastin had shown encouraging results in a Phase II trial in treating a type of kidney cancer. The study found that the combination had a "manageable safety profile" when used for locally advanced or metastatic renal cell carcinoma (mRCC). The tests showed promising effectiveness compared with the standard treatment for mRCC, sunitinib, which is sold by Pfizer under the brand name Sutent.
- Business Wire•yesterdayPhase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma
Genentech, a member of the Roche Group , today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ® plus Avastin® and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma .
- Investor's Business Daily•2 days ago
A handful of products define the new market for drugs that harness the immune system to fight cancer. Here's a list of the drugs and their FDA-approved uses.
RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||30.29 - 30.55|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.75|
|Dividend & Yield||1.02 (3.34%)|
|1y Target Est||N/A|